Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- 30th European Nephrology Conference will be held August 27-28 in Berlin Posted 02-17-2026
- An Australian PD patient developed the free Dialysis Health Tracker app Posted 02-17-2026
- Education Critical to Boosting Home Dialysis, Panel Says I Posted 01-16-2026
- The Annual Dialysis Conference Will be in Kansas City, MO February 26 to March 1 Posted 01-16-2026